Immuron Ltd ADR

Yahoo Finance • last month

Apogee Therapeutics Inc. (APGE): Primary Challenger to Established Blockbusters

We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Apogee Therapeutics, Inc. (NASDAQ:APGE) ranks 6th on this list. Elite money managers are aggressively accumulating Apogee Therapeutics, Inc. (NASD... Full story

Yahoo Finance • last month

Immuron Double Digit 3Q Sales Growth

Sales Highlights (unaudited): Global Q3 sales AUD$1.5 million up 16% on prior comparative period (pcp)YTD Mar 2026 sales AUD$5.7 million up 7% on prior comparative period (pcp)Australia Q3 sales AUD$0.9 million up 15% on prior comparativ... Full story

Yahoo Finance • 2 months ago

Artisan Mid Cap Value Fund Sold Bio-Rad Laboratories (BIO) in Q4

Artisan Partners, an investment management company, released its fourth-quarter 2025 investor letter for “Artisan Mid Cap Value Fund”.  A copy of the letter can be downloaded here. The Fund seeks to invest in undervalued companies with sol... Full story

Yahoo Finance • 6 months ago

Immuron (IMRN) Struggles After Announcing Trial Results

We recently published 7 Best ASX Stocks to Buy Right Now.  Immuron Limited (NASDAQ:IMRN) is one of the best ASX stocks. Immuron Limited (NASDAQ:IMRN) is a biotechnology company that provides a medicine to prevent diarrhea and is also deve... Full story

Yahoo Finance • 6 months ago

Immuron New U.S. Department of Defense Award & Clinical Trial Update

Highlights: New US Department of Defense award to develop two new oral therapeutics targeting Campylobacter and ShigellaUniformed Services University P2TD clinical study update MELBOURNE, Australia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Im... Full story

Yahoo Finance • 7 months ago

Immuron IMM-529 IND approved by FDA

Key Points Immuron receives U.S. Food and Drug administration (FDA) approval for IMM-529 Investigational New Drug (IND) application and clinical study may proceedFDA assigned an IND number (032095) for the IMM-529 application IND 32095 is... Full story

Yahoo Finance • 7 months ago

Immuron Announces Clinical Trial Update

IMM-529 IND: currently under review, FDA request for Information – minor updates to clinical protocol completed and submitted Travelan® P2TD (n=851) Uniformed Services University study topline data delayed to the end of November due to U.S... Full story

Yahoo Finance • 7 months ago

Presenting on Emerging Growth Conference 87 Day 2 on October 23; Register to live stream

MIAMI, Oct. 22, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 87th Emerging Growth Conference on October 22 & 23, 2025. The Emerging Growth Conference identifies c... Full story

Yahoo Finance • 7 months ago

Presenting on Emerging Growth Conference 87 Day 1 on October 22. Register to live stream.

MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 87th Emerging Growth Conference on October 22 & 23, 2025. The Emerging Growth Conference identifies c... Full story

Yahoo Finance • 8 months ago

Immuron Q1 FY26 YoY growth

Sales Highlights (unaudited): Global• Q1 sales AUD$2.0 million up 34% on prior comparative period (pcp) Australia • Q1 sales AUD$1.6 million up 52% on pcp Canada• Q1 sales AUD$0.0 million down 92% on pcp USA • Q1 sales AUD$0.4 million up... Full story

Yahoo Finance • 8 months ago

Why Immuron Is Rising In Pre-market?

(RTTNews) - Immuron (IMRN) has submitted an Investigational New Drug application to the FDA for clinical development of IMM-529. The company is proposing the development of IMM-529 for treatment of Clostridioides difficile infection and pr... Full story

Yahoo Finance • 8 months ago

Immuron Submits IMM-529 IND to FDA

Key Points Immuron submits Investigational new drug (IND) application to FDA for clinical development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI)Previous clinical trial data on IMM-529 p... Full story

Yahoo Finance • 8 months ago

Immuron Letter to Shareholders – Projects Update

Highlights: US Tariffs: Immuron does not anticipate any materialimpact from the recently announced US tariffs on pharmaceutical productsTravelan® Clinical Study: Topline results from the Travelan® clinical study conducted by Uniformed Ser... Full story

Yahoo Finance • 8 months ago

Immuron (IMRN) Posts 49% FY2025 Revenue Growth on Travelan Sales

Immuron Limited (NASDAQ:IMRN) is one of the best performing ASX stocks in 2025. The company released its annual report for 2025 on September 25, in which it reported a 49% growth in global revenue for fiscal year 2025. It stated that much... Full story

Yahoo Finance • 9 months ago

Immuron partners with InvestorHub

MELBOURNE, Australia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) advises it has entered into a partnership with InvestorHub, a direct-to-investor engagement software company that provides public companies... Full story

Yahoo Finance • last year

Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Conference on February 18 & 19, 2025. The Emerging Growth Conference identifies... Full story

Yahoo Finance • 2 years ago

Presenting on the Emerging Growth Conference 75 Day 2 on September 26

Emerging Growth MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com, a leading independent small cap media portal, announces the schedule of the 75th Emerging Growth Conference on September 25 & 26, 2024. The Emerging Growth Con... Full story